Mechanical and Pharmacological Revascularization Strategies for Prevention of Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction: Analysis from Index of Microcirculatory Resistance Registry Data
Table 4
Therapeutic strategies for STEMI in study population.
Parameter
Total (N = 160)
High IMR (N = 54)
Low IMR (N = 106)
value
Mechanical strategies
Stent diameter (mm)
3.0 [3.0–3.5]
3.0 [2.8–3.5]
3.0 [3.0–3.5]
0.248
Stent length (mm)
24.0 [18.0–30.0]
24.0 [22.0–33.0]
23.0 [18.0–28.0]
0.090
Pre balloon dilatation, n (%)
118 (73.8%)
37 (68.5%)
81 (76.4%)
0.377
Post balloon dilatation, n (%)
20 (12.5%)
9 (16.7%)
11 (10.4%)
0.376
Direct stenting, n (%)
42 (26.2%)
17 (31.5%)
25 (23.6%)
0.377
Thrombectomy, n (%)
75 (46.9%)
28 (51.9%)
47 (44.3%)
0.464
Thrombectomy + GP IIb/IIIa inhibitor, n (%)
31 (19.4%)
12 (22.2%)
19 (17.9%)
0.611
Pharmacological strategies
Aspirin, n (%)
160 (100.0%)
54 (100.0%)
106 (100.0%)
1.000
Clopidogrel, n (%)
107 (66.9%)
43 (79.6%)
64 (60.4%)
0.023
Third-generation P2Y12 inhibitors, n (%)
53 (33.1%)
11 (20.4%)
42 (39.6%)
0.023
Morphine, n (%)
96 (60.0%)
28 (51.9%)
68 (64.2%)
0.183
GP IIb/IIIa inhibitor, n (%)
34 (21.2%)
15 (27.8%)
19 (17.9%)
0.216
GP, glycoprotein; IMR, index of microcirculatory resistance.
